Aberdeen Group
JAZZ icon

Aberdeen Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Aberdeen Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.6M Buy
114,128
+53,791
+89% +$9.4M 0.03% 407
2025
Q4 		$10.3M Sell
60,337
-5,133
-8% -$787K 0.02% 611
2025
Q3 		$8.63M Buy
+65,470
New +$7.85M 0.01% 630
2024
Q3 		– Sell
-43,636
Closed -$4.66M – 941
2024
Q2 		$4.66M Sell
43,636
-12,526
-22% -$1.38M 0.01% 640
2024
Q1 		$6.76M Sell
56,162
-68
-0.1% -$8.33K 0.01% 615
2023
Q4 		$6.92M Buy
56,230
+45,860
+442% +$5.72M 0.02% 618
2023
Q3 		$1.34M Sell
10,370
-22,453
-68% -$2.99M ﹤0.01% 738
2023
Q2 		$4.07M Buy
32,823
+2,521
+8% +$339K 0.01% 608
2023
Q1 		$4.43M Buy
30,302
+7,397
+32% +$1.09M 0.01% 594
2022
Q4 		$3.65M Buy
22,905
+1,561
+7% +$229K 0.01% 605
2022
Q3 		$2.85M Buy
21,344
+16,368
+329% +$2.49M 0.01% 645
2022
Q2 		$777K Hold
4,976
– – ﹤0.01% 816
2022
Q1 		$774K Hold
4,976
– – ﹤0.01% 849
2021
Q4 		$634K Hold
4,976
– – ﹤0.01% 939
2021
Q3 		$648K Hold
4,976
– – ﹤0.01% 938
2021
Q2 		$884K Sell
4,976
-869
-15% -$151K ﹤0.01% 892
2021
Q1 		$961K Sell
5,845
-202
-3% -$33.2K ﹤0.01% 867
2020
Q4 		$998K Sell
6,047
-151
-2% -$22.5K ﹤0.01% 832
2020
Q3 		$885K Sell
6,198
-7,900
-56% -$979K ﹤0.01% 817
2020
Q2 		$1.56M Sell
14,098
-15,185
-52% -$1.68M ﹤0.01% 735
2020
Q1 		$2.93M Sell
29,283
-2,772
-9% -$358K 0.01% 614
2019
Q4 		$4.79M Buy
32,055
+9,934
+45% +$1.35M 0.01% 606
2019
Q3 		$2.83M Buy
22,121
+3,877
+21% +$520K 0.01% 669
2019
Q2 		$2.6M Sell
18,244
-426
-2% -$57.3K 0.01% 707
2019
Q1 		$2.67M Buy
18,670
+14,972
+405% +$1.95M 0.01% 697
2018
Q4 		$449K Sell
3,698
-33
-0.9% -$4.89K ﹤0.01% 834
2018
Q3 		$627K Sell
3,731
-165
-4% -$28.4K ﹤0.01% 850
2018
Q2 		$671K Buy
+3,896
New +$637K ﹤0.01% 829

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Aberdeen Group's JAZZ Position: Q1 2026 in Review

Aberdeen Group increased its Jazz Pharmaceuticals (JAZZ) stake by 89% in Q1 2026, buying an estimated $9.4M and bringing the position to 114,128 shares worth $21.6M. The position accounts for 0.03% of the portfolio, ranked #407.

Aberdeen Group first reported a position in JAZZ in Q2 2018 and has held it in 28 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Aberdeen Group held 114,128 shares of Jazz Pharmaceuticals worth $21.6M as of Q1 2026.
  • Aberdeen Group bought 53,791 Jazz Pharmaceuticals shares in Q1 2026, an estimated $9.4M.
  • Jazz Pharmaceuticals made up 0.03% of Aberdeen Group's portfolio in Q1 2026, its #407 holding.
  • Aberdeen Group first reported a position in Jazz Pharmaceuticals in Q2 2018 and has held it in 28 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.